Accéder au contenu
Merck

Oct4-Mediated Inhibition of Lsd1 Activity Promotes the Active and Primed State of Pluripotency Enhancers.

Cell reports (2020-02-06)
Lama AlAbdi, Debapriya Saha, Ming He, Mohd Saleem Dar, Sagar M Utturkar, Putu Ayu Sudyanti, Stephen McCune, Brice H Spears, James A Breedlove, Nadia A Lanman, Humaira Gowher
RÉSUMÉ

An aberrant increase in pluripotency gene (PpG) expression due to enhancer reactivation could induce stemness and enhance the tumorigenicity of cancer stem cells. Silencing of PpG enhancers (PpGe) during embryonic stem cell differentiation involves Lsd1-mediated H3K4me1 demethylation and DNA methylation. Here, we observed retention of H3K4me1 and DNA hypomethylation at PpGe associated with a partial repression of PpGs in F9 embryonal carcinoma cells (ECCs) post-differentiation. H3K4me1 demethylation in F9 ECCs could not be rescued by Lsd1 overexpression. Given our observation that H3K4me1 demethylation is accompanied by strong Oct4 repression in P19 ECCs, we tested if Oct4 interaction with Lsd1 affects its catalytic activity. Our data show a dose-dependent inhibition of Lsd1 activity by Oct4 and retention of H3K4me1 at PpGe in Oct4-overexpressing P19 ECCs. These data suggest that Lsd1-Oct4 interaction in cancer stem cells could establish a "primed" enhancer state that is susceptible to reactivation, leading to aberrant PpG expression.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Albumine de sérum bovin, heat shock fraction, protease free, essentially globulin free, pH 7, ≥98%
Sigma-Aldrich
Alkaline Phosphatase Blue Membrane Substrate Solution, sufficient for 400 mL working substrate
Sigma-Aldrich
LSD1 Active human, recombinant, expressed in E. coli, ≥70% (SDS-PAGE)